Prot #MEDI4736-NHL-001: A Phase 1/2, Open Label, Multicenter Study To Assess The Safety And Tolerability Of Durvalumab (Anti-PD-L1 Antibody) As Monotherapy And In Combination Therapy In Subjects With Lymphoma Or Chronic Lymphocytic Leukemia

Project: Research project

Project Details

StatusFinished
Effective start/end date6/30/17 → 6/30/20

Funding

  • ICON plc (Prot #MEDI4736-NHL-001 // Prot #MEDI4736-NHL-001)
  • Celgene International II Sàrl (Prot #MEDI4736-NHL-001 // Prot #MEDI4736-NHL-001)